Genfit S.A. Reports Pipeline Advances
| Field | Detail |
|---|---|
| Company | Genfit S.A. |
| Form Type | 6-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: pipeline-update, press-release
TL;DR
Genfit 6-K: Pipeline progress announced Oct 28, 2025. Details in press release.
AI Summary
Genfit S.A. filed a Form 6-K on October 28, 2025, reporting advances across its pipeline. The filing includes a press release dated October 28, 2025, detailing these advancements. Pascal Prigent, CEO, signed the report.
Why It Matters
This filing indicates progress in Genfit's drug development programs, which could impact future revenue and market position.
Risk Assessment
Risk Level: medium — Pipeline advancements are inherently uncertain and subject to clinical trial outcomes and regulatory approvals.
Key Players & Entities
- Genfit S.A. (company) — Registrant
- Pascal Prigent (person) — Chief Executive Officer
- October 28, 2025 (date) — Filing Date and Press Release Date
FAQ
What specific advances did Genfit S.A. announce in its press release?
The filing indicates that Exhibit 99.1 is a press release dated October 28, 2025, announcing 'Advances Across its' pipeline, but the specific details of these advances are not included in the provided text.
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report on advances across Genfit S.A.'s pipeline, as detailed in an accompanying press release.
Who signed the Form 6-K report on behalf of Genfit S.A.?
Pascal Prigent, Chief Executive Officer of Genfit S.A., signed the report.
What is Genfit S.A.'s principal executive office address?
Genfit S.A.'s principal executive office is located at Parc Eurasanté, 885, avenue Eugène Avinée, 59120 Loos, France.
Does Genfit S.A. file annual reports under Form 20-F or 40-F?
Genfit S.A. files annual reports under cover of Form 20-F, as indicated by the checked box in the filing.
Filing Stats: 145 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2025-10-28 17:10:04
Filing Documents
- f6k_102825.htm (6-K) — 8KB
- exh_991.htm (EX-99.1) — 27KB
- hdr.jpg (GRAPHIC) — 32KB
- footer.jpg (GRAPHIC) — 9KB
- 0001171843-25-006728.txt ( ) — 92KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENFIT S.A. Date: 28 October, 2025 By: /s/ Pascal PRIGENT Name: Pascal PRIGENT Title: Chief Executive Officer